NASDAQ$TCMD
Tactile Systems Technology Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Revenue decreased due to the COVID-19 pandemic, resulting in a net loss for the quarter.
Tactile Systems Technology reported a 22% decrease in total revenue for the second quarter of 2020, primarily due to the impact of the COVID-19 pandemic on healthcare facilities and patient access. The company experienced an operating loss of $8.0 million and a net loss of $13.9 million, which included a $4.0 million non-cash impairment charge. Despite these challenges, the company saw improving trends throughout the quarter and remains cautiously optimistic about the second half of the year.
- Total revenue decreased 22% year-over-year to $35.1 million.
- Flexitouch revenue decreased 24% year-over-year to $31.1 million.
- Operating loss was $8.0 million, compared to an operating income of $3.0 million in the second quarter of 2019.
- Net loss was $13.9 million, compared to a net income of $2.8 million in the second quarter of 2019.
Headline financials
Revenue & EPS history
Tactile Systems · Revenue · Quarterly
$35.1M
Revenue by segment
Tactile Systems · $68.3M total across 2 segments · Q2 2023
- Lymphedema products$60M+16.2%87.8%
- Airway clearance products$8.34M+4.1%12.2%
Forward guidance
The company expects the COVID-19 pandemic to continue impacting their financial and operational results and cannot reliably estimate the future impact of the pandemic on its operations and financial results at this time.
Tailwinds
- Well-capitalized to weather the crisis.
- Confident in the attractive long-term opportunity.
- Plan to continue investing for growth.
- Focusing on the expansion of commercial organization.
- Leveraging virtual education, selling and service opportunities.
Headwinds
- COVID-19 pandemic is expected to continue to impact financial and operational results.
- Cannot predict the extent to which COVID-19 will impact the business over the near-term.
- Healthcare facilities and clinics restricting access to their clinicians.
- Reducing patient consultations.
- Closing temporarily due to COVID-19.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+3.1%
Avg return
Earnings day
+3.6%
Avg return
5 days after
+5.9%
Avg return
30 days after
64%
29 / 45 earnings
Positive
+40.6%
Q3 2025
Best reaction
-29.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.2% | +14.5% | +12.2% | |
| Q4 2025 | +17.4% | +2.2% | -7.0% | |
| Q3 2025 | +40.6% | +57.6% | +70.0% | |
| Q1 2025 | -29.0% | -31.6% | -27.5% | |
| Q4 2024 | -13.3% | -16.6% | -25.6% | |
| Q3 2024 | -8.6% | +2.2% | +29.5% | |
| Q2 2024 | +7.2% | +8.6% | +8.4% | |
| Q1 2024 | +1.1% | -2.6% | -15.2% | |
| Q4 2023 | -5.4% | +8.0% | +12.6% | |
| Q3 2023 | -22.8% | -16.9% | +1.3% | |
| Q2 2023 | -14.7% | -10.2% | -10.1% | |
| Q1 2023 | +14.0% | +15.7% | +29.6% | |
| Q4 2022 | +2.4% | +7.6% | +13.5% | |
| Q3 2022 | +17.8% | +27.5% | +49.9% | |
| Q2 2022 | +18.2% | +15.0% | +6.5% | |
| Q1 2022 | +2.4% | -22.9% | -41.8% | |
| Q4 2021 | +7.3% | +29.9% | +30.6% | |
| Q3 2021 | -22.9% | -22.1% | -44.1% | |
| Q2 2021 | -9.1% | -10.8% | -8.6% | |
| Q1 2021 | -7.5% | -2.4% | -9.0% | |
| Q4 2020 | -10.4% | -15.0% | -13.7% | |
| Q3 2020 | +5.4% | -2.7% | +14.4% | |
| Q2 2020 | -13.3% | -8.4% | -9.9% | |
| Q1 2020 | -1.0% | +3.2% | +4.8% | |
| Q4 2019 | -2.8% | -6.3% | -28.2% | |
| Q3 2019 | +7.8% | +12.4% | +35.8% | |
| Q2 2019 | -9.6% | -7.6% | -11.3% | |
| Q1 2019 | +4.5% | +4.0% | -4.6% | |
| Q4 2018 | +0.4% | +2.9% | -27.5% | |
| Q3 2018 | -7.9% | -5.6% | -18.2% | |
| Q2 2018 | +13.4% | +12.4% | +37.6% | |
| Q1 2018 | +20.0% | +26.8% | +41.2% | |
| Q4 2017 | +7.8% | +1.6% | -0.8% | |
| Q3 2017 | -10.4% | -7.6% | -1.1% | |
| Q2 2017 | +17.4% | +7.7% | +19.3% | |
| Q1 2016 | +13.9% | +22.1% | +31.1% | |
| Q1 2017 | +13.9% | +22.1% | +31.1% | |
| Q1 2015 | +17.7% | +10.2% | +6.1% | |
| Q4 2016 | +17.7% | +10.2% | +6.1% | |
| Q4 2014 | +17.7% | +10.2% | +6.1% | |
| Q3 2015 | +7.6% | +2.1% | -11.1% | |
| Q3 2016 | +7.6% | +2.1% | -11.1% | |
| Q4 2015 | +6.8% | +3.9% | +31.8% | |
| Q2 2016 | +6.8% | +3.9% | +31.8% | |
| Q2 2015 | +6.8% | +3.9% | +31.8% | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro